Thomas Jefferson University

Jefferson Digital Commons
Department of Pathology, Anatomy, and Cell
Biology Faculty Papers

Department of Pathology, Anatomy, and Cell
Biology

1-1-2009

Graft-versus-Host Disease-Like Pattern in Mycophenolate Mofetil
Related Colon Mucosal Injury: Role of FISH in Establishing the
Diagnosis.
Kathryn C Behling
Thomas Jefferson University

Dorothy M J Foster
Thomas Jefferson University

Tina B Edmonston
Thomas Jefferson University
Follow this and additional works at: https://jdc.jefferson.edu/pacbfp

Agnieszka K Witkiewicz

Part of
the Medical
Anatomy Commons, Medical Cell Biology Commons, and the Medical Pathology
Thomas
Jefferson
University
Commons

Let us know how access to this document benefits you
Recommended Citation
Behling, Kathryn C; Foster, Dorothy M J; Edmonston, Tina B; and Witkiewicz, Agnieszka K, "Graftversus-Host Disease-Like Pattern in Mycophenolate Mofetil Related Colon Mucosal Injury: Role
of FISH in Establishing the Diagnosis." (2009). Department of Pathology, Anatomy, and Cell
Biology Faculty Papers. Paper 117.
https://jdc.jefferson.edu/pacbfp/117
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Pathology, Anatomy, and Cell Biology Faculty Papers by an authorized
administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.

Case Rep Gastroenterol 2009;3:418–423
DOI: 10.1159/000260903

Published online: December 9, 2009

© 2009 S. Karger AG, Basel
ISSN 1662–0631
www.karger.com/crg

Graft-versus-Host Disease-Like
Pattern in Mycophenolate
Mofetil Related Colon Mucosal
Injury: Role of FISH in
Establishing the Diagnosis
Kathryn C. Behling Dorothy M.J. Foster
Tina B. Edmonston Agnieszka K. Witkiewicz
Department of Pathology, Thomas Jefferson University, Philadelphia, Pa., USA

Key Words
Mycophenolate mofetil · Graft-versus-host disease · Fluorescence in situ hybridization ·
Heart transplantation · Colitis
Abstract
Mycophenolate mofetil (CellCept쏐), a commonly used immunosuppressive drug in solid
organ transplantation, has recently been shown to cause graft-versus-host disease
(GVHD)-like changes in the gastrointestinal tract. On rare occasions, true GVHD has also
been documented in the gastrointestinal tract of solid organ transplant patients.
Because the treatment for these two entities is different, i.e. removal of the offending
agent versus the administration of steroids, proper identification of the cause is
imperative. We present a case of mycophenolate mofetil colitis mimicking grade I GVHD
of the gut. In our study, we used fluorescence in situ hybridization for the Y chromosome
to document the lack of male donor lymphocytes in the female recipient colon biopsy.
We suggest that molecular techniques including fluorescence in situ hybridization could
be used to discriminate between MMF-related colitis and true GVHD in order to help
guide therapy.

Introduction

Mycophenolate mofetil (MMF), a commonly used immunosuppressive drug in solid
organ transplantation, has resulted in a significant decrease in allograft rejection. MMF is
an antimetabolite that inhibits inosine monophosphate dehydrogenase, resulting in
blockade of the de novo pathway of purine synthesis. Because this pathway is exclusively
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used by B and T lymphocytes for purine synthesis, MMF administration causes selective
inhibition of lymphocyte proliferation [1]. Gastrointestinal side effects, including
diarrhea, are common with MMF and are caused by specific (suppression of de novo
purine synthesis) and nonspecific (immunosuppressive) effects of the drug on the
gastrointestinal tract [1]. MMF-related colitis has many features in common with
graft-versus-host disease (GVHD) colitis seen in patients who have undergone allogeneic
bone marrow transplantation, including crypt architectural disarray, gland distortion
with lamina propria fibrosis and edema, increased lamina propria inflammation, and
increased crypt epithelial apoptosis [2–4]. Some have also found enterocyte atypia,
increased neuroendocrine cells, and microvascular injury [2, 3]. We report a case of colitis
with features consistent with both MMF colitis and GVHD in a patient receiving MMF as
part of an immunosuppressive regimen after heart transplantation. Because the recipient
was female and the donor was male, we used fluorescence in situ hybridization (FISH) for
the Y chromosome to determine the origin of the lymphocytes present within the colon
biopsy. The presence or absence of donor lymphocytes in colonic lesions in conjunction
with clinical data could help to determine the cause of the patient’s colitis and guide
treatment.

Case Report
The patient was a 69-year-old woman with a past medical history significant for osteopenia, chronic
lower back pain and diverticulosis who presented with weakness and fatigue for approximately one
month accompanied by low blood pressure (70/40 mm Hg) and mild shortness of breath. The patient
had a history of a left heart catheterization in 2007 which showed dilated nonischemic cardiomyopathy
with an ejection fraction of approximately 30%. On the last admission prior to transplantation, the
patient was hypotensive and had an ejection fraction of 15%. She was started on dobutamine, and an
implantable cardioverter-defibrillator device was placed. The patient was ultimately maintained on
milrinone and evaluated for orthotopic heart transplantation.
Once a heart became available for transplantation, the patient was started on prednisone, MMF, and
tacrolimus. A heart from a male donor was transplanted without complication. The explanted heart
showed dilated cardiomyopathy with cardiomyopathy of end-stage heart failure. The patient’s
postoperative course was complicated by an upper extremity deep venous thrombosis for which the
patient received enoxaparin 60 mg subcutaneous every 12 h. The patient was discharged to home on
postoperative day eight on valgancyclovir, pravastatin, iron sulfate, enoxaparin, nystatin, diltiazem-SR,
Bactrim-DS, aspirin, lexapro, and an immunosuppressive regimen including tacrolimus 4 mg every
12 h, a prednisone taper, and MMF 750 mg every 12 h.
Two months after transplantation, the patient presented with a two-week history of watery stools
and diarrhea consisting of four to five episodes after each meal with occasional maroon blood in the
stool. These episodes were preceded by cramping, nonradiating abdominal pain and were not
accompanied by fevers, chills, nausea, vomiting, hematemesis, melena, chest pain, shortness of breath,
dizziness, palpitations, dysuria, or hematuria. She had a history of hemorrhoids and diverticulitis in the
past and had also had a recent colonoscopy which was negative. There was no history of NSAID use or
peptic ulcer disease. Microscopic studies of her stool were negative for Giardia lamblia, Entamoeba
histolytica, ova and parasites, Salmonella spp., Shigella spp., Cryptosporidium, Campylobacter spp., as
well as C. difficile toxin and antigen and Rotatvirus antigen. There was no increase in white blood cells
in the stool. The stool was Hemoccult-positive. An abdominal X-ray demonstrated no intestinal
obstruction. A colonoscopy performed at this time showed severe diverticulosis, and biopsies revealed
colonic mucosa with crypt apoptosis, lamina propria fibrosis, and inflammatory cell infiltrate which
could be consistent with GVHD. No evidence of cytomegalovirus was identified. The patient was
treated with three days of outpatient steroids. Her MMF was held prior to discharge due to leukopenia.
The patient was readmitted three days later with bloody, Hemoccult-positive stools. Colonoscopy
and esophagogastroduodenoscopy failed to demonstrate a source of bleeding. It was felt that the
patient’s symptoms, including bleeding and bloating, were due to MMF, and her immunosuppressive
regimen was change to tacrolimus and azathioprine with amelioration of her gastrointestinal symptoms.
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FISH for the X and Y chromosome was performed on paraffin-embedded tissue prepared in the
histology lab at Thomas Jefferson University Hospital. The slides were subjected to deparaffinization
using Hemo-D (three washes, 10 min each) and 100% ethanol (two washes, 5 min each). The slides were
pretreated as follows: 0.2 N HCl for 20 min at room temperature followed by a wash in 2× SSC for 3 min
at room temperature; 2× SSC at 73°C for 30 min; 30% pepsin in 2× SSC for 30 min at 45°C followed by a
wash in 2× SSC for 3 min at room temperature; proteinase K for 20 min at 45°C followed by a wash in
2× SSC for 3 min at room temperature. The slides were postfixed in 10% formalin for 10 min at room
temperature and washed in 2× SSC for 3 min at room temperature. The slides were dehydrated and
denatured and prepared for hybridization with CEP X and CEP Y Dual color probe (1:10 dilution)
(Vysis, Des Plaines, Ill., USA) overnight at 37°C. The slides were washed in posthybridization buffer for
2 min at 72°C and counterstained with 4c,6-diamidino-2-phenylindole.
Microscopic examination of the random colon biopsies revealed colonic mucosa with areas of crypt
apoptosis and lamina propria fibrosis (fig. 1). There was a mixed inflammatory cell infiltrate
predominately composed of mature lymphocytes. No viral inclusions were identified, and a special
immunohistochemcial stain for cytomegalovirus was negative (data not shown).
Because the patient was female and the donor was male, FISH was performed to detect the presence
of the Y chromosome in lymphocytes present in the biopsy material. Gender-mismatched
transplantations, in which a female patient receives a male donor organ, offer a unique opportunity to
investigate recipient tissues, because the detection of the Y chromosome discriminates the cells of donor
origin from recipient-derived cells. No Y chromosome signals were detected, indicating there was no
significant infiltrate by cells derived from the male heart donor (fig. 1).

Discussion

MMF, a commonly used immunosuppressive drug for solid organ transplantation, has
resulted in a dramatic decrease in graft rejection. MMF acts by inhibiting inosine
monophosphate dehydrogenase resulting in selective inhibition of the de novo pathway
for purine synthesis. Purine synthesis can occur via the de novo and/or the salvage
pathway in most cells. However, lymphocytes are unique in that they almost exclusively
use the de novo pathway. Therefore, administration of MMF results in selective inhibition
of lymphocyte proliferation [1].
Gastrointestinal side effects are common with MMF administration. These effects are
due to specific and nonspecific effects of MMF on the gastrointestinal tract. One
nonspecific effect is increased immunosuppression leading to increased susceptibility of
the gastrointestinal mucosa to infection by microorganisms and viruses. Increased
immunosuppression does not increase susceptibility to any single organism but results in
more likely infection with less pathogenic organisms as well as increased symptomatology
in cases where infections may have remained subclinical [1].
MMF also has specific effects on enterocytes. These cells are approximately 50%
dependent on the de novo pathway for purine synthesis. Because enterocytes have a high
turnover rate, inhibition of proliferation by MMF can have a dramatic effect on mucosal
integrity. Interestingly, after administration, the highest concentrations of MMF have
been found in the gastrointestinal tract, which may exacerbate the effect of MMF on these
cells [1].
There is some evidence that in lymphocytes, with increasing exposure to MMF there is
induction of inosine monophosphate dehydrogenase expression which may counteract
the effects of MMF. Some feel that this may also occur in enterocytes which may explain
the decrease in additional incidence of gastrointestinal side effects after 6 months of MMF
usage [1].
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There has been limited examination of the histologic findings associated with
MMF-related colitis with several groups reporting GVHD-like histology [2–4]. In one
study, MMF colitis showed a significant difference in crypt cell apoptosis, gland
distortion, epithelial cell atypia, the number of neuroendocrine cells, and lamina propria
inflammation as compared to matched controls. This morphology significantly overlaps
with that seen in GVHD [2]. A later study demonstrated that despite the overlap in
histologic features, certain findings such as crypt cell apoptosis and the number of
apoptotic cells were increased with GVHD as compared to MMF exposure. This study
also found that mucosal architectural disarray, epithelial cell atypia, lamina propria
inflammation, number of intraepithelial lymphocytes, number of neuroendocrine cells,
mononuclear cell apoptosis, and microvascular injury were also increased in both patients
with GVHD and those exposed to MMF as compared to controls [3]. A recent study
showed that in patients exposed to MMF, GVHD-like histology can be seen throughout
the gastrointestinal tract including the stomach and esophagus [5].
Some may argue that the histologic findings that some are attributing to MMF toxicity
may actually be due to GVHD. As opposed to bone marrow transplantation, GVHD is
uncommon in solid organ transplantation [6–8]. Billingham [9] suggested that three
criteria must be met in order for GVHD to occur: (1) presence of HLA differences
between the host and donor, (2) presence of immunocompetent donor cells, and
(3) suppression of the host immune system. These criteria are easily met in bone marrow
transplants that are not HLA-matched since a competent immune system is transplanted
along with other marrow elements necessary for effective hematopoiesis. In solid organ
transplantation, a small number of immunocompetent cells are present in transplanted
organs. Also, due to logistical concerns, the organs are often not HLA-matched. Some
solid organs carry more lymphoid tissue, which explains the larger number of reported
cases of GVHD in liver, small bowel, and heart-lung as opposed to kidney and heart
transplantations [6, 7]. Immunocompetent cells within the donor organ migrate into host
tissues relatively quickly after transplantation. GVHD in these cases usually occurs 1–12
weeks after transplantation [6]. The presence of donor lymphocytes has been documented
in recipient tissue using HLA antibodies and short tandem repeat analysis [6–8]. The
presence of these lymphocytes has correlated with the presence of GVHD in these
recipients [6–8].
In the current case, the patient began to experience diarrhea approximately 8 weeks
after transplantation. Infectious etiologies were ruled out, and a colon biopsy
demonstrated findings consistent with grade 1 GVHD. Because the recipient was female
and the donor was male, we were able to determine the origin of lymphocytes present
within the colon biopsy using a probe for the Y chromosome. We decided against using
short tandem repeat analysis, which is commonly employed for bone marrow
engraftment studies, because the colon biopsy was paraffin-embedded, which would have
reduced our ability to adequately amplify DNA present within the biopsy. Examination of
the peripheral blood for donor lymphocytes was not performed due to the unavailability
of this specimen at the time of our study. Ultimately, we showed that there was no
significant donor lymphocyte infiltrate in the recipient colon biopsy. This finding
together with the improvement of the patient’s symptoms subsequent to removal of MMF
from the patient’s immunosuppressive regimen suggest that MMF toxicity, as opposed to
GVHD, was the cause of the patient’s colitis. Although the patient was also administered
steroids subsequent to the colon biopsy for possible GVHD, we feel that given the lack of
donor lymphocytes in the colon biopsy, the rapid improvement in symptoms subsequent
to MMF withdrawal, and the rarity of GVHD in heart transplantation, MMF toxicity is a
much more likely cause of the patient’s symptomatology.
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In the current case, we found that there is substantial overlap between the histologic
findings present in GVHD and MMF-related colitis. Molecular techniques, including
FISH where appropriate, can be employed to demonstrate the presence or absence of
donor lymphocytes. Molecular findings properly correlated with clinical and morphologic
findings can help direct therapy which may include withdrawal of the offending agent, in
the case of MMF-related colitis, or administration of steroids, in the case of GVHD.

Fig. 1. GVHD-like histology in MMF toxicity of the colon. a There is a mixed inflammatory infiltrate
composed primarily of mature lymphocytes and eosinophils. The arrow indicates an apoptotic
enterocyte within a crypt. The inset shows a higher magnification of a crypt with an apoptotic
enterocyte (hematoxylin-eosin, original magnifications 200× (inset 400×)). b FISH for detection of the
X (red) and Y (green) chromosome (XX/XY) in lymphocytes of the lamina propria. Only the
X chromosome is detected in lymphocytes of the lamina propria in this specimen.
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